European Journal of Histochemistry (ISSN: 1121-760X; E-ISSN: 2038-8306) is a distinguished peer-reviewed scholarly journal published by PAGEPRESS PUBL based in Italy. Since its inception in 1992 and with a commitment to Open Access since 2010, the journal has played a pivotal role in disseminating high-quality research in the fields of Histology, Biophysics, and Cell Biology. As of 2023, the journal holds a commendable position within the academic community, achieving Q2 rankings in Biophysics, Histology, and Medicine (miscellaneous), further highlighting its relevance and impact in these critical areas of research. Despite its HIndex not being specified, its Scopus rankings demonstrate the journal's competitive edge, particularly in Histology (Rank #33/62) and Biophysics (Rank #84/152). The journal aims to provide a platform for researchers to share innovative findings and contribute to the enrichment of knowledge in histochemical methodologies and their application to biomedical sciences. Its Open Access model ensures the broadest possible dissemination of research, making it an essential resource for researchers, professionals, and students alike who are engaged in the life sciences. For more information, visit the journal's webpage hosted by PAGEPRESS PUBL.

TISSUE & CELL is a prominent academic journal, published by CHURCHILL LIVINGSTONE, that has been at the forefront of research in the fields of cell biology, developmental biology, and miscellaneous areas of medicine since its inception in 1969. With a strong focus on high-quality research, TISSUE & CELL has established itself within the academic community, holding a Q3 ranking in both Cell Biology and Developmental Biology, and a Q2 ranking in Medicine as of 2023. The journal aims to disseminate significant findings that contribute to the understanding of tissue structure and function, helping to bridge the gap between basic biological research and clinical applications. While it operates on a subscription basis and does not currently offer Open Access options, the journal remains a vital resource for researchers, professionals, and students interested in cutting-edge developments in the biological sciences. The journal's address is located in the scenic city of Edinburgh, further establishing its academic heritage in the United Kingdom.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

Welcome to the JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, a premier platform for the dissemination of cutting-edge research in the fields of anatomy and histology. Published by SAGE PUBLICATIONS LTD, this esteemed journal has been a cornerstone of academic inquiry since its inception in 1953 and continues to play a vital role in advancing our understanding of cellular structure and function. With an impressive Impact Factor reflected in its rank as Q1 in both Anatomy and Histology categories, the journal ranks #5 out of 48 in Medicine Anatomy and #17 out of 62 in Medicine Histology, making it an essential resource for researchers and professionals alike. The journal provides a rigorous peer-review process and encourages submissions that enhance the scientific community's knowledge. As a vital resource for students, professionals, and researchers focusing on histochemical methodologies, the JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY offers insights into the latest advancements and critical debates within this dynamic discipline.

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Protein & Cell, published by Oxford University Press, is a distinguished international journal focusing on cutting-edge research in the fields of biochemistry, biotechnology, cell biology, and drug discovery. This open access journal, active since 2014, is dedicated to disseminating innovative findings that advance our understanding of protein functions and cellular processes, making it an essential resource for researchers, professionals, and students alike. With an impressive 2023 impact factor reflected in its Q1 ranking across multiple categories such as Biochemistry, Drug Discovery, and Cell Biology, 'Protein & Cell' stands at the forefront of scientific research, driving collaboration and discussion in the scientific community. Researchers can access the journal freely online, fostering a global exchange of knowledge and contributing to significant advancements in medicine and biotechnology. Located in the United Kingdom, the journal strives to be a pivotal platform for impactful research that influences future studies and applications.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.